Literature DB >> 29303805

Randomized Trial of Division Versus Nondivision of Short Gastric Vessels During Nissen Fundoplication: 20-Year Outcomes.

Stephen P Kinsey-Trotman1, Peter G Devitt2, Tim Bright1, Sarah K Thompson2, Glyn G Jamieson2, David I Watson1.   

Abstract

OBJECTIVE: To evaluate late outcomes from a randomized trial of division versus no division of short gastric vessels during laparoscopic Nissen fundoplication at up to 20 years follow-up.
BACKGROUND: Nissen fundoplication is an established procedure for the treatment of gastroesophageal reflux disease. Controversy about whether side effects such as dysphagia could be reduced by division of the short gastric vessels led to the establishment of a randomized trial in 1994. Early results showed equivalent reflux control and dysphagia, but more bloating after vessel division.
METHODS: A total of 102 patients underwent a laparoscopic Nissen fundoplication between May 1994 and October 1995, and were randomized to short gastric vessel division (50) versus nondivision (52). Follow-up was obtained yearly to 20 years using a standardized questionnaire administered by a blinded investigator. Clinical outcomes at 20 years or most recent follow-up were determined.
RESULTS: No significant differences for heartburn symptom and satisfaction scores or medication use were found between treatment groups. At 15 to 20 (mean 19.6) years follow-up, significant differences persisted for epigastric bloating: 26% versus 50% for nondivision versus division groups (P = 0.046). Heartburn symptom scores were low and not different for nondivision versus division groups (mean analog scores 1.4 vs 2.1/10, P = 0.152). Overall satisfaction after surgery was high in both groups (mean analog scores 8.1 vs 8.6/10, P = 0.989).
CONCLUSIONS: Although laparoscopic Nissen fundoplication has durable efficacy for heartburn symptom control at up to 20 years follow-up, division of short-gastric vessels failed to confer any reduction in side effects, and was associated with persistent epigastric bloat symptoms at late follow-up in this trial.

Entities:  

Mesh:

Year:  2018        PMID: 29303805     DOI: 10.1097/SLA.0000000000002648

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

Review 1.  Surgical treatment of GERD: systematic review and meta-analysis.

Authors:  Sophia K McKinley; Rebecca C Dirks; Danielle Walsh; Celeste Hollands; Lauren E Arthur; Noe Rodriguez; Joyce Jhang; Ahmed Abou-Setta; Aurora Pryor; Dimitrios Stefanidis; Bethany J Slater
Journal:  Surg Endosc       Date:  2021-03-02       Impact factor: 4.584

2.  Transient delayed gastric emptying following laparoscopic Nissen fundoplication for gastroesophageal reflux disease.

Authors:  Suyu He; Yingdong Jia; Fei Xu; Qianlong Li; Xin Xiong; Hui Wang; Xiaojuan Jing; Xuejun Yang; Lianfen He; Hanmei Wang; Xin Tao
Journal:  Langenbecks Arch Surg       Date:  2021-04-06       Impact factor: 3.445

3.  Practice-Changing Milestones in Anti-reflux and Hiatal Hernia Surgery: a Single Surgeon Perspective over 27 years and 1200 Operations.

Authors:  Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2021-02-02       Impact factor: 3.452

4.  SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD).

Authors:  Bethany J Slater; Rebecca C Dirks; Sophia K McKinley; Mohammed T Ansari; Geoffrey P Kohn; Nirav Thosani; Bashar Qumseya; Sarah Billmeier; Shaun Daly; Catherine Crawford; Anne P Ehlers; Celeste Hollands; Francesco Palazzo; Noe Rodriguez; Arianne Train; Eelco Wassenaar; Danielle Walsh; Aurora D Pryor; Dimitrios Stefanidis
Journal:  Surg Endosc       Date:  2021-07-19       Impact factor: 4.584

5.  Additional fundophrenicopexia, after Nissen fundoplication, reduces postoperative dysphagia and re-operation rate in the long-term follow up.

Authors:  Milena Nikolic; Aleksa Matic; Ivan Kristo; Matthias Paireder; Reza Asari; Bogdan Osmokrovic; Georg Semmler; Sebastian F Schoppmann
Journal:  Surg Endosc       Date:  2021-06-22       Impact factor: 4.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.